No connection

Search Results

PACB

BEARISH
$1.63 Live
Pacific Biosciences of California, Inc. · NASDAQ
Target $2.5 (+53.4%)
$0.85 52W Range $2.73
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 17, 2026
Market cap
$492.26M
P/E
N/A
ROE
-213.5%
Profit margin
N/A
Debt/Equity
131.32
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
90%
PACB exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and an operating margin of -134.54%. While the company maintains a strong current ratio (5.15) and modest revenue growth (13.8%), these are overshadowed by a catastrophic 5-year price decline of 94.5% and an extreme Price-to-Book ratio of 90.56. There is a stark divergence between the analyst 'Buy' consensus and the bearish insider activity, with the CEO, CFO, and COO all selling shares. The company is currently in a high-risk survival phase with no clear path to profitability.

Key Strengths

Positive year-over-year revenue growth of 13.80%
Strong short-term liquidity with a current ratio of 5.15
Consistent ability to beat earnings estimates (3 of last 4 quarters)
Improving EPS trajectory (YoY growth of 40%, though still negative)
Positive short-term price momentum (1-week change of +20.7%)

Key Risks

Extreme operational inefficiency with an operating margin of -134.54%
Critical financial health failure indicated by a Piotroski F-Score of 1/9
High leverage with a Debt/Equity ratio of 131.32
Severe equity erosion reflected in a -213.45% ROE
Strong bearish signal from C-suite insider selling ($1.28M in sales)
AI Fair Value Estimate
Based on comprehensive analysis
$1.45
-11.0% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
15
Weak
Value
10
Future
45
Past
15
Health
5
Dividend
0
AI Verdict
High Risk / Speculative
Key drivers: Piotroski F-Score 1/9, Negative Operating Margins, Insider Selling, Extreme P/B Ratio
Confidence
95%
Value
10/100

Ref P/E, PEG, Graham Number

Positives
  • Low nominal share price
Watchpoints
  • Price/Book of 90.56 indicates extreme overvaluation relative to assets
  • No P/E or Graham Number due to lack of earnings
Future
45/100

Ref Growth rates

Positives
  • 13.8% Revenue growth
  • Analyst target price of $2.50 suggests perceived upside
Watchpoints
  • High cash burn rate
  • Lack of profitability scaling
Past
15/100

Ref Historical trends

Positives
  • Recent 1-year recovery of +35.8%
Watchpoints
  • 5-year return of -94.5% represents a near-total loss of capital
Health
5/100

Ref Altman Z-Score, Piotroski F-Score

Positives
  • High Current Ratio (5.15)
Watchpoints
  • Piotroski F-Score 1/9
  • Debt/Equity 131.32
  • ROE -213.45%
Dividend
0/100

Ref Yield, Payout

Positives
No standout positives identified.
Watchpoints
  • No dividend history
  • 0/100 dividend strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$1.63
Analyst Target
$2.5
Upside/Downside
+53.4%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for PACB and closest competitors.

Updated 2026-04-16
PAC
Pacific Biosciences of California, Inc.
Primary
5Y
-94.5%
3Y
-85.2%
1Y
+35.8%
6M
-7.4%
1M
+18.1%
1W
+20.7%
ANG
AngioDynamics, Inc.
Peer
5Y
-49.3%
3Y
+20.9%
1Y
+23.6%
6M
+7.9%
1M
+5.1%
1W
+6.4%
KMD
Kamada Ltd.
Peer
5Y
+49.5%
3Y
+95.6%
1Y
+48.0%
6M
+28.6%
1M
+2.3%
1W
+0.2%
BWA
BrainsWay Ltd.
Peer
5Y
+163.4%
3Y
+1289.2%
1Y
+184.8%
6M
+61.0%
1M
-3.2%
1W
-7.8%
AQS
Aquestive Therapeutics, Inc.
Peer
5Y
-27.7%
3Y
+432.4%
1Y
+47.8%
6M
-20.4%
1M
+5.2%
1W
-4.7%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-3.92
PEG Ratio
N/A
P/B Ratio
90.56
P/S Ratio
3.08
EV/Revenue
5.72
EV/EBITDA
-5.41
Market Cap
$492.26M

Profitability

Profit margins and return metrics

Profit Margin N/A
Operating Margin -134.54%
Gross Margin 34.28%
ROE -213.45%
ROA -33.73%

Growth

Revenue and earnings growth rates

Revenue Growth +13.8%
Earnings Growth N/A
Q/Q Revenue Growth +13.82%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
131.32
High debt
Current Ratio
5.15
Strong
Quick Ratio
4.32
Excellent
Cash/Share
$0.93

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
37.1%
Op. Margin
-92.3%
Net Margin
-90.4%
Total Assets
$0.8B
Liabilities
$0.8B
Equity
$0.0B
Debt/Equity
145.58x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
105%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-07
$N/A
2026-02-12
$-0.12
+10.8% surprise
2025-11-05
$-0.12
+15.1% surprise
2025-08-07
$-0.13
+21.5% surprise

Healthcare Sector Comparison

Comparing PACB against 498 companies in the Healthcare sector (28 bullish, 153 neutral, 317 bearish)
Return on Equity (ROE)
-213.45%
This Stock
vs
-95.47%
Sector Avg
+123.6% (Excellent)
Debt to Equity
131.32
This Stock
vs
2.89
Sector Avg
+4447.1% (Higher)
Revenue Growth
13.8%
This Stock
vs
137.48%
Sector Avg
-90.0% (Slower)
Current Ratio
5.15
This Stock
vs
4.66
Sector Avg
+10.5% (Better)

Similar Companies

Peer comparison within the same industry

PACB Pacific...
BEARISH
Mkt Cap
$492M
P/E
-
ROE
-213.5%
Price
$1.63
ANGO AngioDynamics, Inc.
BEARISH
Mkt Cap
$492M
P/E
-
ROE
-15.3%
Price
$11.94
 Compare with PACB
KMDA Kamada Ltd.
NEUTRAL
Mkt Cap
$491M
P/E
24.3
ROE
7.6%
Price
$8.49
 Compare with PACB
BWAY BrainsWay Ltd.
NEUTRAL
Mkt Cap
$491M
P/E
68.1
ROE
11.3%
Price
$12.26
 Compare with PACB
AQST Aquestive...
BEARISH
Mkt Cap
$490M
P/E
-
ROE
-%
Price
$4.02
 Compare with PACB

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

GIBSON CHRISTOPHER
Director
Stock Award
2026-04-08
57,473 shares
GIBSON JAMES R II
Chief Financial Officer
Sell
2026-04-01
88,185 shares · $120,813
HENRY CHRISTIAN O
Chief Executive Officer
Sell
2026-03-03
12,497 shares · $18,920
VAN OENE MARK D
Chief Operating Officer
Sell
2026-03-03
6,504 shares · $9,847
GIBSON CHRISTOPHER
Director
Stock Award
2026-03-03
53,913 shares
FARMER MICHELE CPA
Officer
Sell
2026-03-03
2,979 shares · $4,510
HENRY CHRISTIAN O
Chief Executive Officer
Stock Award
2026-02-27
920,810 shares
GIBSON JAMES R II
Chief Financial Officer
Stock Award
2026-02-27
333,848 shares
VAN OENE MARK D
Chief Operating Officer
Stock Award
2026-02-27
500,000 shares
FARMER MICHELE CPA
Officer
Stock Award
2026-02-27
89,835 shares
HENRY CHRISTIAN O
Chief Executive Officer
Sell
2026-02-18
472,667 shares · $752,390
VAN OENE MARK D
Chief Operating Officer
Sell
2026-02-18
184,897 shares · $294,318
FARMER MICHELE CPA
Officer
Sell
2026-02-18
50,167 shares · $79,856
Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K
8-K
2026-03-06

Pacific Biosciences of California, Inc. filed an 8-K on March 6, 2026, likely to announce its fourth-quarter and full-year financial results.

8-K
8-K
2026-03-05

Pacific Biosciences of California, Inc. filed an 8-K likely reporting its fourth-quarter and full-year financial results.

10-K
10-K
2026-02-25

Pacific Biosciences (PACB) filed its 10-K annual report on February 25, 2026. The provided excerpts reference the business operations, risk factors, and management's discussion and analysis sections, but no specific financial metrics or risk details were included in the text.

8-K
8-K
2026-02-12

Pacific Biosciences of California, Inc. likely reported its fourth quarter and full-year financial results.

8-K
8-K
2026-02-03

Pacific Biosciences (PACB) filed an 8-K on February 3, 2026, likely to announce its fourth quarter and full-year financial results.

8-K
FORM 8-K
2026-02-02

Pacific Biosciences of California, Inc. reported its fourth quarter and full-year 2025 financial results.

8-K
8-K
2026-01-12
10-Q
10-Q
2025-11-06

Pacific Biosciences (PACB) filed its 10-Q quarterly report on November 6, 2025. The filing includes a section detailing risk factors under Item 1A, although specific financial highlights and risk descriptions were not provided in the available excerpt.

8-K
8-K
2025-11-05

Pacific Biosciences of California, Inc. likely filed this 8-K to announce its third-quarter 2025 financial results.

10-Q
10-Q
2025-08-07

Pacific Biosciences (PACB) filed its 10-Q quarterly report on August 7, 2025. The filing includes a dedicated section for risk factors under Item 1A, although specific financial highlights and risk details were not provided in the available excerpts.

8-K
8-K
2025-08-07
8-K
8-K
2025-06-06
10-Q
10-Q
2025-05-12
8-K
8-K
2025-05-08
DEF 14A
DEF 14A
2025-04-23
Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
BUY
6 analysts
Barclays
2026-04-14
Maintains
Underweight Underweight
Barclays
2026-03-06
down
Equal-Weight Underweight
Barclays
2025-12-15
Maintains
Equal-Weight Equal-Weight
Piper Sandler
2025-11-11
Maintains
Neutral Neutral
Stephens & Co.
2025-11-10
Maintains
Overweight Overweight

Past News Coverage

Recent headlines mentioning PACB from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile